Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07616128 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of EVO756 in Adults With Migraine

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 26 → 35 locations
    • Eligibility criteria expanded, about 7 words
  2. Trial sites expanded: 20 → 26 locationsv4
  3. Trial sites expanded: 14 → 20 locations
    • Start date changed from estimate of Jun 2026 to Jul 29, 2026
    v3
  4. Recruitment opened
    • Trial sites expanded: 0 → 14 locations
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Evommune, Inc.
4 trials monitored
See all monitored trials
Migraine
482 trials monitored
See 26 trials at risk
This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.
Trial Details
NCT Number NCT07616128
Lead Sponsor Evommune, Inc.
Conditions
(from sponsor)		 Migraine
Related terms Migraine Disorders, Migraine with Aura, Migraine without Aura
Enrollment 330 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov